The Independent Expert Panel LLC managing disruptive technology The

The Independent Expert Panel, LLC …. managing disruptive technology * * The Innovator’s Dilemma: when new technologies cause great firms to fail CM. Christensen, Harvard Press. 1997 “Even successful cos. sometimes fail to manage disruptive new technologies” The Independent Expert Panel, LLC Cardiovascular Management, Spring 2004 “The way people work has changed, but the [organization] lags far behind” The New Organization- a survey of the company, The Economist, Jan. 2006 Contact Us Jack DeCerce FACHE IXP Project Director 732 462-5717 j.decerce@att.net Capabilities - The Independent Expert Panel, LLC Organizational Structure The Independent Expert Panel operates under a unique partnership drawing upon individual medical, economic and healthcare specialists. Each member has unique professional experience in medical practice, healthcare strategies, financial implications, and advocacy for regulatory / reimbursement approval. Panels organized for each engagement include leading practitioners in current medical practice, who are peer opinion leaders in their discipline. IXP members include: Andrew K. Palmer, MD Professor Orthopedic Surgery, Upstate Medical School, Syracuse, NY Samuel Havens Former President of Prudential Managed Care, Former Chairman AAHP Joanne Vaul, MBA, Health Care Financial Consultant, Surgery Center CFO Kathleen L. Chumer, RN, Clinical Executive, Healthcare Operations and Policy John Grangeia, R.Ph., MS, Pharmacist, former COO University Medical Center Jack De Cerce FACHE, Health Systems CEO / IXP Project Leader Maureen Faul, R.N. President, The Resh Group, healthcare operations George Griffiths Senior Executive Pharmaceuticals / Medical Devices Lisa Sheehan President, Sheehan & Associates, healthcare marketing CBIZ Collaboration national healthcare firm for data and technical content plus healthcare financial expertise www.cbiz.com/kaconsults/ Projects undertaken by the Independent Expert Panel - IXP IXP provides a unique perspective on emerging medical technology. Seasoned Panel members analyze current medical practice and provide data based expert assumptions on the changes in MD practice behavior and financial impact of new products. Detailed financial projections are utilized to create computer models that assist in analyzing the effect of new medical advances. Senior decision-makers seek perspective on anticipated shifts in clinical practice and the changing economics of healthcare. New pharmaceutical therapies and medical devices are “disruptive” to clinical practice behavior and hospital economics. Decision-makers need patient case-mix models to project profitability around new technology. The Panel is regularly called upon for presentations at meetings of healthcare opinion leaders. Successful projects in managing acceptance of “disruptive” technology include: Janssen / Ortho McNeil Pharmaceuticals, Raritan, NJ [Market support of new transdermal drug distribution system] Cordis, a Johnson & Johnson Co., Miami Lakes, Fl. [600 presentations of clinical / economic model on drug-eluting stent] Surgical Services, Inc., Orlando, Fl. [sales / operations impact model for unique endoscopy service] Rightfield Solutions, LLC, Chicago, IL [operations / economic model for healthcare risk management product] Mitsubishi Pharma America, Warren, NJ [Medical opinion leader - focus group on new drug therapy for arterial disease] Health Care Systems, a Johnson & Johnson Co., Piscataway, NJ [Medical School/ Hospital leadership initiative on impact of healthcare innovation] Johnson & Johnson Interventional Systems, Warren, NJ [Hospital management education on the original bare metal coronary artery stent] Publications Michaelis, Vaul, DeCerce, et.al., Disruptive Technology: New Medical Advances are Troublesome for Even the Most Successful Health Systems and Innovator Health Companies, Cardiovascular Management, March – April 2004. Vaul, Kaden. Negotiating Payment for New Technology Purchases, Healthcare Financial Management, December 2002. Chumer, DeCerce. Managing Technological Explosion in the Medical Management of Coronary Artery Disease, Cardiovascular Management, May – June 2002. DeCerce. Best Medical Practices: Managed Care and New Technology, The Need for Disease Life Cycle Economic Models, The AAMA Executive, April / June 1998. Kaden, DeCerce, Zupa. Integrating New Technology with Managed Care Contracting. The Journal of Cardiovascular Management. May / June 1998. Continuing Medical Education “Integrating New Technology with Managed Care Contracting” University of Medicine and Dentistry of New Jersey “Paradigm Shifts in the Treatment of Cardiac and Vascular Disease” University HealthSystems Consortium “New Medical Technologies - a tipping point” Physician Executive Forum “Influence of Disruptive Technologies in Disease Management” TCT, Washington, DC “Maintaining Profitability in Cardiac Services” Cath Lab Digest CME/ CEU May 2003 http://www.cathlabdigest.com/cld/displayArticleaa.cfm?articleID=article1640 The Independent Expert Panel, LLC Standard Operating Protocol Deliver effective research to medical cos., investment entities and healthcare providers Perform data-based financial review Provide independent validation of analysis Convene expert clinical panels to assess market potential of new technology IXP Project Approach Phase A - Discovery o Research contemporary clinical practice o Analyze available research / literature o Recruit / organize expert panel Phase B – Expert Assumptions o Project anticipated changes in medical strategy o Compare current expenses vs. cost of new technology o Develop default value economic model on impact of new product Phase C – Panel Presentation o o o o Test presentation - macro overview of new technology Review IXP expert assumptions on changes in clinical practice / economics Solicit MD / provider customer feedback Update presentation based on customer input The Independent Expert Panel, LLC Provide market support from a MD / hospital customer perspective Medical opinion leader feedback on emerging medical trends Economic analysis based on patient records / provider payment Interpret clinical / economic impact of new medical technology Investor market analysis on future medical devices and drug therapy Decision-maker market-support on changes in disease management Contact Us Jack DeCerce FACHE IXP Project Director 732 462-5717 j.decerce@att.net IXP Client liaison 732 521-2593 george_griffiths@comcast.net George Griffiths